CN104306807A - Compound preparation for treating advanced lung cancer and preparing method thereof - Google Patents

Abstract

The invention provides a compound preparation for treating advanced lung cancer. The compound preparation comprises, by weight, the components of 10-15 parts of Codonopsis pilosula, 15-30 parts of Oldenlandia diffusa, 15-30 parts of nightshade, 15-30 parts of salvia chinensis, 15-30 parts of edible tulip, 15-30 parts of coffee senna, 15-30 parts of Rubus parvifolius, 15-30 parts of duchesnea, 1-3 parts of Chinese yew and 5-10 parts of liquorice. The compound preparation for treating advanced lung cancer has double effects of healthy energy strengthening and anticancer performance. The invention further provides a preparing method of the compound preparation for treating advanced lung cancer. The technology is simple, product quality is stable, and the invention further provides an application of the compound preparation for treating advanced lung cancer in advanced lung cancer anticancer medicine.

Description

A compound preparation for treating advanced lung cancer and its preparation method

technical field

The invention relates to the field of traditional Chinese medicine, in particular to a compound preparation for treating advanced lung cancer. The present invention also relates to a preparation method of a compound preparation for treating advanced lung cancer. The present invention also relates to a compound preparation for treating advanced lung cancer in the preparation of advanced lung cancer. application in medicine. the

Background technique

Lung cancer is one of the most common malignant tumors in the world. It is the main cause of human death due to cancer and one of the most harmful malignant tumors to human health and life. According to statistics, the global incidence of lung cancer in 2011 was 160,800. Currently, platinum-based combination chemotherapy is considered the standard treatment for advanced non-small cell lung cancer, but the overall curative effect shows that the median survival time is less than 10 months, and few patients survive more than 2 years. The curative effect has reached a "bottleneck" period, and the side effects are large. In recent years, the emergence of targeted drugs has broken through the survival bottleneck of chemotherapy to a certain extent, but there are still many problems with targeted drugs, such as being only applicable to specific groups of people, such as EGFR-TKI (epidermal growth factor tyrosinase inhibitor) It is only suitable for patients with EGFR mutation, and there are some problems such as toxic side effects and high price. the

In China, most cancer patients receive TCM treatment. The combination of traditional Chinese medicine with surgery, radiotherapy, chemotherapy, hyperthermia, biological therapy and targeted drugs has shown certain advantages. the

At present, there are various kinds of Chinese patent medicines or Chinese medicine compound prescriptions for the treatment of advanced lung cancer, but most of the Chinese patent medicines contain anti-cancer Chinese herbal medicines in a low proportion, or only have anti-cancer Chinese herbal medicines, resulting in monotonous therapeutic effects and poor results. the

The Chinese patent "Compound preparation of active ingredients of traditional Chinese medicine for the treatment of lung cancer and its preparation method", patent number CN 103054881A, discloses a compound preparation of active ingredients of traditional Chinese medicine for the treatment of lung cancer: 1-3 parts of paclitaxel, 1-3 parts of cinobufaction base, 1-3 parts of triptolide, the formula has the effect of high anticancer activity and wide anticancer spectrum. the

In recent years, along with the research on lung cancer, there are also many patent applications and publications of traditional Chinese medicine preparations for the treatment of lung cancer, and the effect of traditional Chinese medicine in the treatment of lung cancer has been continuously improved. The Chinese patent "a traditional Chinese medicine compound preparation for the treatment of non-small cell lung cancer and its preparation method" , Patent No. CN 102861284A, discloses a traditional Chinese medicine compound preparation for the treatment of non-small cell lung cancer, comprising the following components by weight: 1-10 parts of astragalus, 1-10 parts of heterophylla, 1-10 parts of turmeric, turmeric 1-10 parts of gold, 1-10 parts of 1 raw oyster, 1-10 parts of hive, 1-10 parts of Prunella vulgaris, 1-10 parts of Hedyotis diffusa. Composed of raw oysters, beehives, Prunella vulgaris, Hedyotis diffusa, etc., to achieve the effect of integrating the three traditional Chinese medicine treatment methods of strengthening the body, detoxifying, and removing blood stasis. The combination of the three methods can not only strengthen the body, fight cancer, but also prevent recurrence transfer. the

The inventor has studied the treatment of lung cancer with traditional Chinese medicine for many years. The treatment of "syndrome differentiation + disease differentiation + symptomatic treatment" is the guiding principle. Through epidemiological investigations, we understand the common TCM syndrome types of lung cancer. Corresponding prescriptions, and through years of case collection and analysis, and research, it is known that among the lung cancer cases in recent years, the type of qi deficiency and phlegm dampness is the most, accounting for about 76.3%, followed by the type of deficiency of both qi and yin, the type of yin deficiency and toxic heat, and the type of lung cancer. Qi stagnation and blood stasis type: The analysis of the syndrome types of advanced patients found that the Qi deficiency and phlegm dampness type is the most, followed by the Qi and Yin deficiency type, Qi stagnation and blood stasis type, Yin deficiency toxin heat type and heat toxin flaming type. The traditional Chinese medicine syndrome type of advanced lung cancer is mainly qi deficiency and phlegm dampness type, which is mainly lung and spleen spleen deficiency, heat toxin, phlegm dampness, and blood stasis as the standard. the

According to the dialectical thought above, it has become the focus and difficulty of research to distinguish the TCM syndrome types of advanced lung cancer, so as to formulate targeted prescriptions that conform to the syndrome types, so as to achieve the effect of strengthening the body and fighting cancer. the

Contents of the invention

The present invention proposes a compound preparation for the treatment of advanced lung cancer. Starting from the overall concept, syndrome differentiation is used for treatment, and syndrome differentiation and disease differentiation are combined to achieve the purpose of containing both strengthening Chinese herbal medicine and anticancer Chinese herbal medicine. the

The invention also provides a preparation method of the compound preparation for treating advanced lung cancer, which is convenient for preparation and stable in product quality. the

The invention also proposes the application of a compound preparation for treating advanced lung cancer. the

The present invention is achieved in the following manner:

A compound preparation for treating advanced lung cancer, comprising the following components by weight: 10-15 parts of Codonopsis pilosula, 15-30 parts of Hedyotis diffusa, 15-30 parts of Solanum solanum, 15-30 parts of Shi Jianchuan, Shanci 15-30 parts of mushrooms, 15-30 parts of Wangjiangnan, 15-30 parts of Snake Paul, 15-30 parts of snake berry, 1-3 parts of yew, 5-10 parts of licorice. the

In order to further improve the effect, the inventor optimized and adjusted the formula. After adjustment, it is: Codonopsis 10-15 parts, Atractylodes macrocephala 10-15 parts, Radix Astragali 15-30 parts, Hedyotis diffusa 15-30 parts, Solanum nigrum 15-30 parts. 30 servings, 15-30 servings of Shi Jianchuan, 15-30 servings of Shanzi Mushroom, 15-30 servings of fried barley, 15-30 servings of Wangjiang River, 15-30 servings of Snake Berry, 15-30 servings of Snakeberry, Taxus 1-3 parts, 5-10 parts of licorice. the

More preferably: 15 parts of Codonopsis pilosula, 15 parts of Atractylodes macrocephala, 30 parts of Astragalus membranaceus, 30 parts of Hedyotis diffusa, 30 parts of Solanum nigrum, 30 parts of Shi Jianchuan, 30 parts of Shanzi mushroom, 30 parts of fried barley, and 30 parts of Jiangnan , 30 parts of Snake Paule, 30 parts of Snakeberry, 3 parts of Taxus, 10 parts of Licorice. the

The compound preparation for the treatment of advanced lung cancer is based on the guiding principle of "syndrome differentiation + disease differentiation + symptomatic" treatment, through epidemiological investigations to understand the common TCM syndrome types of lung cancer, combined with the syndrome types, with "combination of disease and syndrome" as the guiding ideology, the proposed Prescription. In terms of syndrome differentiation, using a retrospective research method, the inventor collected lung cancer cases hospitalized in Guangdong Provincial Hospital of Traditional Chinese Medicine from January 2002 to December 2007, and conducted research on 435 cases that met the inclusion criteria. Accounted for about 76.3%, followed by deficiency of both qi and yin, deficiency of yin and toxin-heat, and stagnation of qi and blood stasis. In addition, an analysis of the syndrome types of 207 patients with advanced stage found that the type of qi deficiency and phlegm-damp was the most, followed by the combination of qi and yin. Deficiency type, qi stagnation and blood stasis type, yin deficiency toxin-heat type and heat-toxin flaming type. The traditional Chinese medicine syndrome type of advanced lung cancer is mainly qi deficiency and phlegm dampness type, which is mainly lung and spleen spleen deficiency, heat toxin, phlegm dampness, and blood stasis as the standard. The present invention proceeds from the overall concept of syndrome differentiation and treatment, and combines syndrome differentiation and disease differentiation. Syndrome differentiation uses Codonopsis pilosula, Radix Astragali, Atractylodes macrocephala, and licorice to invigorate the spleen and lungs. To identify diseases, use Shanzi mushroom, Hedyotis grass, Solanum nigrum, Shijianchuan, snakeberry, snakehead, fried coix seed, Wangjiangnan and yew to clear away heat and detoxify, remove dampness and blood stasis, dispel stagnation and fight tumors. The whole prescription combines strengthening the body with eliminating pathogenic factors, and combining disease differentiation and syndrome differentiation. Fuzheng focuses on nourishing the Qi of the spleen and lungs, while eliminating pathogenic factors mainly focuses on clearing away heat and detoxification, removing dampness, dispelling blood stasis and resolving stagnation. The combined use of traditional Chinese medicine plays the role of strengthening the body and fighting cancer, which can be widely used in patients with advanced lung cancer, or combined with modern medical treatment methods. Jointly play the role of attenuation and synergism. the

In addition, in terms of the selection and proportion of the components, the inventor has also gone through repeated demonstrations and practices. In terms of the selection and quantification of Codonopsis ginseng, for example, 30 parts of Radix Pseudostellaria was used to replace Codonopsis pilosula, but the effect is not as good as that of Codonopsis pilosula. The reason is that Chinese medicine believes that The effect of Codonopsis is to nourish the middle and replenish Qi, invigorate the spleen and lungs; Taizishen nourishes Qi and promotes body fluid. Therefore, Chinese medicine currently believes that Radix Pseudostellaria tends to produce body fluid, and its effect of nourishing qi is not as good as Codonopsis ginseng; replacing Wangjiangnan with August Zha can also achieve a certain effect, but in terms of safety and long-term curative effect, it is not as good as Wangjiangnan, because August Zha Efficacy Soothing the liver and regulating qi, promoting blood circulation and relieving pain, Wangjiangnan reduces swelling and detoxification, its effect of reducing swelling and detoxification is better than that of August Zhaxin, and August Zhaxin dissipates Qi, tumor patients often have Qi deficiency, and long-term use can aggravate the symptoms of Qi deficiency; Snakeberry has The effect of reducing swelling and detoxification also has a certain anti-tumor effect. In terms of the effect of reducing swelling and detoxification, Curcuma can also achieve this effect, but Curcuma promotes Qi and blood, and lung cancer patients are prone to hemoptysis, and hemoptysis patients are forbidden to use Curcuma. In actual use, curcuma is not as effective as snakeberry; the extract paclitaxel of yew (artificially planted and processed) has better antitumor effect, so the present invention adds yew to enhance the antitumor effect. the

The preparation method of the compound preparation for the treatment of advanced lung cancer comprises the following steps:

i. Take the full amount of prescription medicinal materials, add 10-12 times the amount of water and soak for 20-30 minutes;

ii. Heat to boiling and decoct for 100-120min;

iii. Separate the decoction, continue to decoct the dregs with water twice, add 6-8 times the amount of water each time and decoct for 60 minutes, and combine the decoction;

iv. The decoction is concentrated under reduced pressure at low temperature, and the concentrated solution is collected;

i. The concentrated solution is spray-dried, and the dry powder is collected. the

Preferably, in step i, add 12 times the amount of water and soak for 30 minutes. the

Preferably, in step ii, decocting for 120min. the

Preferably, in step iii, add 8 times the amount of water each time for decocting. the

Each gram of dry powder in this batch is equivalent to 3.22-6.26 points of medicinal materials, and the dry powder can be packaged. the

Application of the compound preparation for treating advanced lung cancer in the preparation of drugs for advanced lung cancer. the

The beneficial effects of the present invention are:

The compound preparation for the treatment of advanced lung cancer of the present invention has dual functions of rectifying the body and anticancer, especially for the traditional Chinese medicine syndromes such as Qi deficiency and phlegm dampness type, Qi and Yin deficiency type, etc., which are mainly manifested in the current advanced lung cancer. Curative effect; In addition, the compound preparation for the treatment of advanced lung cancer of the present invention has the effect of Fuzheng Kangai prescription for treating advanced lung cancer, which can alleviate the patient's symptoms, improve the quality of life, and prolong the survival period. Combined with in vitro high-frequency hyperthermia, it can improve life Quality, combined with chemotherapy or targeted drugs (EGFR-TKI) can play a role in attenuating or synergizing. the

In the preparation method of the compound preparation for treating advanced lung cancer of the present invention, the whole process can be completed by machines, the preparation is convenient, the production process is consistent each time, and the quality is stable. the

The application of the compound preparation for treating advanced lung cancer of the present invention in the preparation of drugs for advanced lung cancer has the effects of improving drug efficacy and reducing side effects. the

Detailed ways

The technical solutions in practice of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without creative efforts fall within the protection scope of the present invention. the

Example 1

According to the formula disclosed in the present invention and the preparation method, the contriver makes the finished product of embodiment 1 through the following process:

Take the following components:

Codonopsis 15 parts, Atractylodes macrocephala 15 parts, Astragalus membranaceus 30 parts, Hedyotis diffusa 30 parts, Solanum nigrum 30 parts, Shi Jianchuan 30 parts, Shanzi mushroom 30 parts, fried barley 30 parts, Wangjiangnan 30 parts, Snake Paul 30 parts 30 parts of snakeberry, 3 parts of yew, 10 parts of licorice. the

Then prepare by the following steps:

i. Take the full amount of prescription medicinal materials, add 12 times the amount of water and soak for 30 minutes;

ii. Heat to boiling and decoct for two hours;

iii. Separate the decoction, continue to decoct the dregs with water twice, each time add 8 times the amount of water to decoct for one hour, and combine the decoction;

iv. The decoction is concentrated under reduced pressure at low temperature, and the concentrated solution is collected;

v. The concentrate is spray-dried and the dry powder is collected. the

This batch of dry powder per gram is equivalent to 6.458 points of medicinal materials, and the dry powder is subpackaged into small bags with ziplock bags, and every 6 bags are sealed with composite bags to obtain the finished product of Example 1. the

Example 2

Take the following components:

10 parts of Codonopsis, 15 parts of Hedyotis diffusa, 15 parts of Solanum nigrum, 15 parts of Shi Jianchuan, 15 parts of Shanzi Mushroom, 15 parts of Wangjiang River, 15 parts of Snake Poule, 15 parts of snakeberry, 1 part of Chinese yew, licorice 5 servings. the

Then prepare by the following steps:

i. Take the full amount of prescription medicinal materials, add 10 times the amount of water and soak for 20 minutes;

ii. Heat to boiling and decoct for 100min;

iii. Separate the decoction, continue to decoct the dregs with water twice, add 6 times the amount of water each time and decoct for one hour, and combine the decoction;

iv. The decoction is concentrated under reduced pressure at low temperature, and the concentrated solution is collected;

v. The concentrate is spray-dried and the dry powder is collected. the

The dry powder is sub-packed into small bags with a ziplock bag, and every 6 bags are packed and sealed with a composite bag to obtain the finished product of Example 2. the

Example 3

Take the following components:

12 parts of Dangshen, 12 parts of Atractylodes macrocephala, 22 parts of Astragalus, 25 parts of Hedyotis diffusa, 20 parts of Solanum nigrum, 20 parts of Shi Jianchuan, 20 parts of Shanzi mushroom, 20 parts of fried barley, 20 parts of Wangjiangnan, 23 parts of snake paole 23 parts of snakeberry, 2 parts of yew, 8 parts of licorice. the

Prepared by the following steps:

i. Take the full amount of prescription medicinal materials, add 11 times the amount of water and soak for 25 minutes;

ii. Heat to boiling and decoct for 110min;

iii. Separate the decoction, continue to decoct the dregs with water twice, add 7 times the amount of water each time and decoct for 60 minutes, and combine the decoction;

iv. The decoction is concentrated under reduced pressure at low temperature, and the concentrated solution is collected;

v. The concentrate is spray-dried and the dry powder is collected. the

The dry powder is sub-packed into small packets with a ziplock bag, and every 6 packets are sealed with a composite bag to obtain the finished product of Example 3. the

For the therapeutic effect of this compound preparation for the treatment of advanced lung cancer, the inventor has carried out many years, continuous, and multiple experiments, all of which have positive therapeutic effects, especially in terms of cooperation with chemotherapy and targeted therapy. The above three implementations The finished product of the example, especially the finished product of the best embodiment 1, only represent some embodiments within the scope disclosed by the present invention, rather than all embodiments, as long as they belong to the scope of protection disclosed by the present invention, they are all included in the protection list, for To verify the therapeutic and auxiliary effects of the finished product of the present invention, the inventor conducted the following experimental demonstration. the

Experiment 1

Cell experiment verification

By measuring the effect of the compound preparation for treating advanced lung cancer on promoting apoptosis of human non-small cell lung cancer cell lines, the data are as follows:

The analysis table of the compound preparation for the treatment of advanced lung cancer on the apoptosis rate of three kinds of lung cancer cells

in:

i. Cell A549 is: human lung adenocarcinoma cell; H1650 is: human lung cancer (epidermal) cell; PC9 is: human lung cancer cell. the

ii. The finished product ratio of Example 1 was adopted in this experiment. the

Experiment 2

Experimental verification of different concentrations of cells

The apoptosis-promoting effect of different doses of compound preparations on human non-small cell lung cancer cell lines was determined. As the dose increased, the apoptosis-promoting effect was more obvious. The data are as follows:

The analysis table of different doses of the compound preparation for the treatment of advanced lung cancer on the apoptosis rate of three kinds of lung cancer cells

in:

i. Cell A549 is: human lung adenocarcinoma cell; H1650 is: human lung cancer (epidermal) cell; PC9 is: human lung cancer cell. the

ii. Concentration 1 drug dosage: Codonopsis 10 parts, Atractylodes macrocephala 10 parts, Astragalus 15 parts, Hedyotis diffusa 15 parts, Solanum nigrum 15 parts, Shi Jianchuan 15 parts, Shanzi mushroom 15 parts, fried barley 15 parts, Wangjiangnan 15 parts, 15 parts snake berry, 15 parts snake berry, 1 part yew, 5 parts licorice. the

iii. Concentration 2 drug dosage: 10 parts of Codonopsis pilosula, 10 parts of Atractylodes macrocephala, 20 parts of Astragalus membranaceus, 20 parts of Hedyotis diffusa, 20 parts of Solanum nigrum, 20 parts of Shi Jianchuan, 20 parts of Shanzi mushroom, 20 parts of fried barley, Wangjiangnan 20 parts, 20 parts of Snake Paul, 20 parts of snakeberry, 2 parts of yew, 5 parts of licorice. the

iv. Concentration 3 drug dosage: Codonopsis 15 parts, Atractylodes macrocephala 15 parts, Astragalus membranaceus 30 parts, Hedyotis diffusa 30 parts, Solanum nigrum 30 parts, Shi Jianchuan 30 parts, Shanzi mushroom 30 parts, fried barley 30 parts, Wangjiangnan 30 parts, 30 parts of Snake Paule, 30 parts of Snakeberry, 3 parts of Taxus, 10 parts of Licorice. the

Experiment 3

Retrospective analysis shows that the combination of the present invention and chemotherapy can improve the survival period of patients with advanced lung cancer. the

The inventor carried out a retrospective analysis to 435 routine patients who received Chinese medicine treatment (the Chinese medicine decoction of more than 80% patients was added and subtracted with the prescription of the present invention) in the Oncology Department of Guangdong Provincial Hospital of Traditional Chinese Medicine from January, 2002 to December, 2007. October 30, 2008. There were 83, 160, and 192 patients at and before stage IIIA, stage IIIB, and stage IV, accounting for 19.1%, 36.8%, and 44.1% of all non-small cell lung cancer patients, respectively; adenocarcinoma and squamous cell carcinoma were the most pathological types, 94.5%. The 6-month survival rate of 435 patients with non-small cell lung cancer was 51.0%, and the 1-year survival rate was 37.0%. The median survival time was 12.0 months. The 6-month survival rate of the TCM group: 39.0%, and the 1-year survival rate: 25.0%. The median survival time was 8.0 months. The 6-month survival rate of the integrated traditional Chinese and Western medicine group: 63.0%, 1-year survival rate: 49.0%. The median survival time was 14.0 months. The median survival time of the combined traditional Chinese and Western medicine group was higher than that reported in the literature for cisplatin-based combined chemotherapy. the

Experiment 4

In the early stage, the present invention combined with targeted drugs was used to treat advanced non-small cell lung cancer, indicating that the present invention has a certain detoxification and synergistic effect on targeted drugs. the

In 2009, the inventor received 19 patients with advanced non-small cell lung cancer who had not received other treatments, received Chinese medicine treatment combined with epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib 250mg) treatment, and found that Chinese medicine combined EGFR-TKI first-line treatment of advanced non-small cell lung cancer with unknown EGFR status has considerable curative effect and few adverse reactions. After further inclusion of cases, 70 patients with advanced NSCLC will be included in the interim analysis in 2012. All 70 patients were confirmed by histopathological or cytological examination, and 49 of them fully met the criteria of the dominant population, that is, Oriental race, female, glandular Cancer patients and non-smokers; 21 non-conforming persons were regarded as non-dominant population, and they all accepted Fuzheng Kangai Prescription, the compound preparation (250ml, qd) combined with gefitinib (250mg, qd) for the treatment of advanced lung cancer of the present invention. the

The result of this experiment:

Among the 49 patients in the dominant population, CR was 0, PR was 16 (32.7%), SD was 30 (61.2%), PD was 3 (6.1%), ORR was 32.7%, DCR was 93.9%; median disease progression-free survival The time (PFS) was 8.2 months, and the median survival period after treatment was 9.9 months. Among the 21 non-dominant patients, CR was 0, PR was 5 (23.8%), SD was 9 (42.9%), PD was 7 (33.3%), ORR was 23.8%, and DCR was 66.7%. The progression survival time (PFS) was 4.6 months, and the median survival time after treatment was 7.9 months. There is a statistical difference between the two. In the first-line treatment, the objective response rate of the dominant population and the non-dominant population were consistent, both being 21.4%. Toxic and side effects are mild and tolerable, most of which are grade 1-2. Symptoms are relieved after symptomatic treatment and do not affect treatment. The curative effect of Kangai Fuzheng Recipe combined with gefitinib in the treatment of advanced non-small cell lung cancer patients is better than that of non-dominant patients. the

The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of the present invention. within the scope of protection. the

Claims (8)

1. A compound preparation for the treatment of advanced lung cancer, characterized in that it comprises the following components in parts by weight: 10-15 parts of Codonopsis Codonopsis, 15-30 parts of Hedyotis diffusa, 15-30 parts of Solanum solanum, 15 parts of Shi Jianchuan -30 parts, 15-30 parts of Shanzi mushroom, 15-30 parts of Wangjiang River, 15-30 parts of Snake Paule, 15-30 parts of snakeberry, 1-3 parts of yew, 5-10 parts of licorice. 2. A compound preparation for treating advanced lung cancer, characterized in that it comprises the following components in parts by weight: 10-15 parts of Codonopsis pilosula, 10-15 parts of Atractylodes macrocephala, 15-30 parts of Radix Astragali, and 15-30 parts of Hedyotis diffusa , 15-30 parts of Solanum nigrum, 15-30 parts of Shi Jianchuan, 15-30 parts of Shanzi Mushroom, 15-30 parts of fried barley, 15-30 parts of Wangjiang River, 15-30 parts of Snake Paule, 15-30 parts of Snakeberry 30 parts, 1-3 parts of yew, 5-10 parts of licorice. 3. A compound preparation for the treatment of advanced lung cancer, characterized in that it comprises the following components in parts by weight: 15 parts of Codonopsis pilosula, 15 parts of Atractylodes macrocephala, 30 parts of Radix Astragali, 30 parts of Hedyotis diffusa, 30 parts of Solanum nigrum, and 30 servings of pepper, 30 servings of Shanzi mushroom, 30 servings of fried barley, 30 servings of Jiangnan, 30 servings of Snakeberry, 30 servings of snakeberry, 3 servings of yew, and 10 servings of licorice. 4. The preparation method of the compound preparation for treating advanced lung cancer as described in any one of claims 1-3, is characterized in that, comprises the following steps: i. Take the full amount of prescription medicinal materials, add 10-12 times the amount of water and soak for 20-30 minutes; ii. Heat to boiling and decoct for 100-120min; iii. Separate the decoction, continue to decoct the dregs with water twice, each time add 6-8 times the amount of water to decoct for 60 minutes, and combine the decoction; iv. The decoction is concentrated under reduced pressure at low temperature, and the concentrate is collected; v. The concentrate is spray-dried and the dry powder is collected. 5. the preparation method of the compound preparation for the treatment of advanced lung cancer as described in claim 4, is characterized in that: In step i, add 12 times the amount of water and soak for 30 minutes. 6. the preparation method of the compound preparation for the treatment of advanced lung cancer as described in claim 4, is characterized in that: In step ii, decoct for 120min. 7. the preparation method of the compound preparation for the treatment of advanced lung cancer as described in claim 4, is characterized in that: In step iii, add 8 times the amount of water each time for decocting. 8. The application of the compound preparation for treating advanced lung cancer as described in any one of claims 1-3 in the preparation of drugs for advanced lung cancer.